2014 - 2013 HCV Genotypes and Treatment
Treating HCV genotypes 1-6
Links to treatment options for all HCV genotypes is provided, using clinical research found published online in peer-reviewed journals and presented at conferences, as well as interactive learning activities.
Related - Genotype 4 research updates
Also See AASLD Nov 2013 Meeting Update
Genotype 4 HCV Achieve High Virologic Response Rates With Sofosbuvir Plus RBV for 12 or 24 Weeks
Interim virologic response rates appeared higher in patients treated for 24 weeks vs 12 weeks and were independent of previous treatment status, the presence of cirrhosis, or other prognostic factors.
How to optimize HCV therapy in genotype 4 patients
Gamal Esmat1,2,*, Mohamed El Kassas2, Mohamed Hassany2, Mohamed Esmat Gamil2,
Maisa El Raziky1
Article first published online: 3 JAN 2013DOI: 10.1111/liv.12059
HCV is a worldwide disease with an estimated prevalence by WHO of 3%. Hepatitis C virus 4 is prevalent in Africa and the Middle East, especially Egypt. The treatment of HCV4 is affected by many factors, related to the virus itself (genotype, pretreatment viral load and prevalent quasispecies), to the host (genetic factors, age, ethnicity and liver histology), to the presence of comorbidities (obesity, insulin resistance and co-infections) and to the therapeutic drugs (type, dose and duration). Optimizing treatment is the goal of daily practice to obtain the best results for the patient.
- direct acting anti-viral drugs
- diabetes mellitus
- early virological response
- hepatitis C virus
- HCV genotype 1
- HCV genotype 4
- homeostasis model assessment-IR
- interleukin 28-b
- insulin resistance
- IFN/RBV resistance-determining region
- occult hepatitis B virus infection
- pegylated interferon
- rapid virological response
- sustained virological response
- quality-adjusted life years
HCV is a global disease whose morbidity and mortality are increasing. The World Health Organization estimated that 3% of the world's population or approximately 130–170 million people were chronically infected with HCV at the end of the 20th century, and 2.3–4.7 million new infections per year. Hepatitis C virus is also responsible for 300 000 deaths annually . Six major genotypes have been identified worldwide and HCV-4 is the predominant HCV genotype in the Middle East and Africa, especially Egypt . Treatment of HCV with pegylated interferon (PEG-IFN) and ribavirin (RBV) represents the cornerstone and the standard of care (SOC) for the management of all HCV genotypes . Response to treatment varies, and the incremental cost-effectiveness of combination therapy with PEG-IFN for men ranged from 26 000–64 000 dollars per quality-adjusted life years (QALY) for genotype 1 and from 10 000–28 000 dollars per QALY for other genotypes, respectively, and, for women, 32 000–90 000 dollars for genotype 1 and 12 000–42 000 dollars for other genotypes respectively . The relatively high cost of treatment with PEG-IFN/RBV regimens, the frequent side effects during and after therapy and the psychological impact on non-responders make it essential to optimize results by optimizing patient selection. Optimization HCV treatment is an ongoing issue in daily clinical practice based on determining how, who and when to treat.
Predictors of treatment response
Treatment decisions should be based on criteria and factors that affect the likelihood of treatment outcome. The treatment of HCV4 is affected by many Host/Virus factors that must be precisely evaluated and optimized before treatment initiation.
Like HCV1, HCV4 was previously considered to be one of the most difficult-to-treat genotypes. However, the new protease inhibitors (telaprevir and boceprevir) have significantly improved treatment outcome in patients with HCV1, so that today HCV4 lags behind all other genotypes .
Baseline viral load
Available data on the assessment of viral load as a predictor of treatment response suggest that high baseline viral load (most studies use a cut-off value of 400 000 IU/ml) is a negative predictive factor for treatment outcome [5-8].
The presence of multiple HCV species in the pretreatment serum of HCV4 patients could be a major cause of HCV4 resistance to treatment. Greater sequence heterogeneity generates diverse quasispecies, providing a reservoir of mutations that enable virus-escape from antiviral therapy [9, 10].
Genetic factors (IL28B - IP-10- NS5A sequence heterogeneity)
Polymorphisms in the region of the IL28B gene have been associated with PEG-IFN and RBV treatment response in genotype 1 HCV infections. In a unique well-characterized cohort of HCV4 patients, a recent study evaluated the association of the IL28B polymorphism and the response to treatment or the severity of liver disease . This study included 164 HCV4 patients from different ethnic groups (Egyptian, European and Sub-Saharan African). Among these patients, 82 were studied for response and 160 for disease severity. These data showed that the IL28B rs12979860 CC genotype was associated with a better treatment response. The response rates were 81.8, 46.5 and 29.4% for genotype CC, CT and TT respectively. No significant relationship was found between rs12979860 and the severity of disease. Analysis of IL28B genotype could be used as a guide to treatment in these patients. Another genetic factor, IP-10 (CXCL10 – a chemokine active on lymphocytes) in plasma and intrahepatic IP-10 mRNA are elevated in patients with chronic HCV genotype 1/4 who do not achieve a sustained viral response (SVR) . More recent data on viral genetic polymorphisms, especially within core and NS5A regions, have been shown to influence the response to PEG-IFN/RBV. In a study by El Shamy et al. on 43 Egyptian patients with HCV4 treated with PEG-IFN/RBV, sliding window analysis over the carboxy-terminus of the NS5A protein identified the PEG-IFN/RBV resistance-determining region (IRRDR) as the most prominent region associated with a SVR. Twenty-one/25 patients (84%) with SVR and only 5/18 patients (28%) without a SVR were infected with HCV with IRRDR containing 4 or more mutations (IRRDR≥4) (P = 0.0004). Multivariate analysis identified IRRDR≥4 as an independent predictor of SVR. The positive predictive value of IRRDR≥4 for SVR was 81% (21/26; P = 0.002), whereas the negative predictive value for non-SVR was 76% (13/17; P = 0.02). These results suggest that IRRDR≥4 could be a useful predictive marker for a SVR in patients with HCV4 infection treated with PEG-IFN/RBV .
Although it is an important factor for treatment outcome, it should be evaluated on a case-by-case basis in relation to the patient's level of activity and life style. Papastergiou et al.  evaluated 177 HCV4 patients in a retrospective study and the results of treatment were poor in patients ≥45 years old. Wirth et al.  evaluated PEG-IFN α2b/RBV in children and adolescents (3–17 years) with chronic hepatitis C and showed that it was effective (SVR in G1 53%; G2/3 93%; G4 80%) and safe.
New data are available on the effect of ethnicity on treatment outcome. Dimitroulopoulos et al..  studied sixty patients with chronic HCV genotype 4a (30 Europeans – Group A; and 30 Egyptians – Group B) treated with PEG-IFNα2a/RBV for a fixed duration of 48 weeks. The RVR was 26.7% vs. 30.0% and the EVR 23.3% vs. 16.7%, respectively, while the SVR was 36.7% vs. 26.7% respectively (P = 0.59). This study did not show any significant difference in SVR between the two groups. This Greek group confirmed the results in a retrospective study  in 177 chronic HCV genotype 4 patients, 42.9% of whom were Egyptian and the rest Greek. Once again, no difference was found between the two groups. Two comparative French studies evaluated Egyptian vs. European or African ethnicity, and showed that Egyptian ethnicity was a favourable predictor for treatment outcome [17, 18].
Patients with advanced fibrosis have lower SVR rates. One of the first studies to determine the predictors of response in HCV genotype 4 was performed by Gad et al.  using multivariate logistic regression analysis to select independent predictive factors of SVR. This study concluded that fibrosis (> F2 Metavir), severe steatosis, treatment with standard interferon and high serum AFP levels were all negatively associated with SVR.
Obesity reduces treatment efficacy. Hepatic steatosis increases the necroinflammatory process of HCV and accelerates the development of fibrosis, and obesity probably affects the immune response through the development of leptin resistance . Steatosis is common in patients with genotype 4 HCV and significantly improves after HCV eradication. Steatosis appears to be related to high BMI, rather than viral load or the degree of liver injury .
Insulin resistance (IR)
IR is probably one of the most important negative predictive factors of HCV treatment outcome. Controlling diabetes mellitus (DM) and improving IR help in improving treatment response. In a cohort of 40 treatment naive patients with chronic hepatitis C genotype 4 infection (20 patients with well-controlled type 2 DM and 20 patients without), no difference was found in SVR between patients with and without diabetes suggesting that well-controlled DM does not seem to reduce the SVR . Another trial was performed in 131 non-diabetic, genotype 4 HCV patients treated with PEG-IFNα2b/RBV to evaluate IR (using HOMA-IR) as a predictor of response to treatment, this study showed that IR strongly predicts the achievement of RVR and SVR, thus further confirming the value of IR as a factor to determine treatment outcome . This hypothesis was also established in another trial in which an insulin-sensitizing agent (Pioglitazone) was added to IFN/RBV to improve IR , there was a significant increase in RVR and SVR in this study compared with patients who received SOC (IFN/RBV).
HIV & HBV are the most common blood-borne diseases in combination with HCV. In Egypt, Transmission and prevalence of HIV is still very low (<0.1% in the population between 15 and 49 years old) , HBV prevalence in Egypt ranges between 2–8% of the population . Interestingly, HCV infection may suppress and/or reduce HBV DNA replication . Although it is generally agreed that the presence of HBV markers in chronic HCV patients may be a negative predictor for response to treatment , trials to confirm this hypothesis in HCV genotype 4 are lacking. Occult hepatitis B virus infection (OBI) is defined as the presence of HBV DNA in serum and/or liver tissue without detectable HBsAg, with or without anti-HBc or anti-HBs outside the preseroconversion window period . An Egyptian study of 155 chronic HCV genotype 4 patients, 3.9% with OBI and treated with PEG-IFN/RBV, showed that the presence of occult hepatitis B infection had no significant influence on non-response to PEG-IFN/RBV. There is a high proportion of schistosomiasis and HCV co-infection in Egypt. A retrospective study was performed including 3596 chronic HCV4 patients treated with (PEG-IFN/RBV) with positive anti-Schistosomal antibodies in 27.3%. An early virological response (EVR) was achieved in 79% of patients with positive schistosomal serology vs. 83% of those with negative schistosomal serology (P = 0.013). The rate of virological breakthrough at week 24 was higher in patients with a positive schistosomal serology (48% vs. 37.5%) (P < 0.01) and end of treatment response was achieved in 47% of patients with positive schistosomal serology vs. 57% in those with negative Schistosomal serology (P < 0.01). Multivariate logistic regression analysis showed that positive schistosomiasis was significantly associated with treatment failure . Another associated pathogen that should be studied is H. Pylori infection. A recent study in the liver specimens of 85 patients tested for the presence of the H. pylori DNA Cag A gene showed that there was a direct correlation between the presence of the H. pylori DNA Cag A gene and the severity of liver fibrosis and necro-inflammation, especially in chronic HCV patients . Further trials are needed to test the relationship between H. Pylori infection and response to HCV treatment.
Pegylated interferon and the addition of Ribavirin significantly improve the results of HCV4 treatment. Recent progress in the management of HCV with the introduction of new direct inhibitors of HCV replication has also improved the management of HCV4 . There are many compounds in phase II and III trials, mainly HCV NS3/4A protease inhibitors [32, 33]. Most of these new antiviral drugs have been developed and investigated for genotype-1 HCV. Although both Telaprevir and Boceprevir are not approved for Genotype 4, Telaprevir was shown to be active against HCV4 after 15 days of monotherapy or in combination with PEG-IFN/RBV compared with PEG-IFN, RBV and placebo . A total of 24 patients were studied (8 patients in each arm), ethnicity varied (38% Egyptians, 25% Caucasian) and none of the patients had cirrhosis. Although the population was small, the results of this proof of concept study suggest that larger trials should be performed with telaprevir in HCV4. Preliminary data have suggested that results in HCV4 may not be comparable with the present regimen of boceprevir [the other approved direct acting antiviral drugs (DAAD)] . TMC435, another new oral NS3/4A protease inhibitor is in phase III clinical trials for the treatment of HCV infection. The phase IIa study (TMC435-C202) investigated the antiviral activity, safety, tolerance and pharmacokinetics of TMC435 monotherapy in treatment-naïve patients infected with HCV genotypes 2–6. For the primary end point at day 8, the mean (±SD) change in plasma HCV RNA (log10IU/ml) from baseline was the greatest in genotypes 6 (−4.35 ± 0.29) and 4 (−3.52 ± 0.43), then genotypes 2 (−2.73 ± 0.71) and 5 (−2.19 ± 0.39) with no antiviral activity for genotype 3 .
Adherence to treatment has been shown to be one of the most positive predictors of outcome to treatment. Numerous worldwide studies agree with the 80/80/80 rule (>80% of IFN, >80% of RBV, >80% of treatment duration) [20, 37].
Most of the recent guidelines depend on HCV genotyping to determine treatment duration [38, 39]. The SOC for the treatment of genotype 4 is similar to that of genotype 1 (48 weeks of therapy). This is the recommended duration based on the results of most large published randomized, international, phase III trials of combined PEG-IFN α2/RBV in the management of chronic HCV patients [6, 7, 40]. However, only a few HCV genotype 4 patients were included in these studies. Assessment of the virological response at weeks 4 and 12 of therapy is an easy and reliable tool to individually tailor treatment. Patients who become HCV-RNA negative (<50 IU/ml by qualitative PCR assay) or have more than a 2 log decrease in serum HCV-RNA level by quantitative PCR assay after 12 weeks of therapy (partial EVR) are defined as having an early virological response (EVR). Failure to achieve an EVR is predictive of patients who are unlikely to achieve a successful outcome with combination therapy. Patients who are HCV-RNA negative after 4 weeks of treatment have a RVR. A RVR is predictive of a successful outcome with combination therapy . The probability of achieving a SVR is mostly dependent upon when the patient becomes HCV-RNA negative. For example, patients who become HCV-RNA negative after 4 weeks of treatment will achieve a SVR more frequently than those who become HCV-RNA negative after 12 weeks. SVR rates are much lower in patients who do not clear HCV RNA during the first 12 weeks of treatment. Completely negative HCV RNA at week 12 (complete EVR) is a better predictor of achieving a SVR 6 months after treatment than a partial EVR. The SVR rate in patients with a RVR was 91, 75%, in those with a complete EVR and only 27% in patients with a partial EVR and negative virus at week 24 .
Very few randomized controlled trials results are available in patients with HCV-4 that report a viral response at week 4. As long as no other predictors of poor response exist, patients with HCV-4 who achieve a RVR are potential candidates for shortened 24-week regimens [43, 44]. The advantages of shorter treatment in these patients are an increase in tolerance and decrease in cost. Slow responders who are not HCV-RNA negative at week 4 or 12 are potential candidates for extending treatment up to 72 weeks, although there are no reliable data to support this option.
Many factors help to identify a good response to HCV4 treatment. These may be virus related, host related, drug related or because of the presence of comorbidities. A better knowledge of predictors of treatment response (virus and host related) is mandatory . Factors that can be modified (e.g. body weight, drug adherence, control of DM, patient counselling, etc.) before treatment should improve treatment optimization.
The authors have no disclosure.
Global surveillance and control of hepatitis C. Report of a WHO consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium. J Viral Hepat 1999; 6: 35–47.
McOmish F, Yap PL, Dow BC, et al. Geographical distribution of hepatitis C virus genotypes in blood donors: an international collaborative survey. J Clin Microbiol 1994; 32: 884–92.
Esmat G, El Raziky M, El Kassas M, Hassany M, Gamil ME. The future for the treatment of genotype 4 chronic hepatitis C. Liver Int 2012; 32(Suppl. 1): 146–50.
Salomon JA, Weinstein MC, Hammitt JK, Goldie SJ. Cost-effectiveness of treatment for chronic hepatitis C infection in an evolving patient population. JAMA 2003; 290: 228–37.
Kamal SM, El Tawil AA, Nakano T, et al. Peginterferon alpha-2b and ribavirin therapy in chronic hepatitis C genotype 4: impact of treatment duration and viral kinetics on sustained virological response. Gut 2005; 54: 858–66.
Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975–82.
Hadziyannis SJ, Sette H Jr., Morgan TR, et al. PEGASYS International Study Group. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140: 346–55.
Hasan F, Asker H, Al-Khaldi J, et al. Peginterferon alfa-2b plus ribavirin for the treatment of chronic hepatitis C genotype 4. Am J Gastroenterol 2004; 99: 1733–7.
Fan X, Mao Q, Zhou D, et al. High diversity of hepatitis C viral quasispecies is associated with early virological response in patients undergoing antiviral therapy. Hepatology 2009; 50: 1765–72.
Al-Qahtani AA, Kessie G, Dela Cruz D, Al-Faleh FZ, Al-Ahdal MN. Quasispecies of genotype 4 of hepatitis C virus genomes in Saudi patients managed with interferon alfa and ribavirin therapy. Ann Saudi Med 2010; 30: 109–14.
Asselah T, De Muynck S, Broët P, et al. IL28B polymorphism is associated with treatment response in patients with genotype 4 chronic hepatitis C. J Hepatol 2012; 56: 527–32.
Lagging M, Askarieh G, Negro F, et al. Response prediction in chronic hepatitis C by assessment of IP-10 and IL28B-related single nucleotide polymorphisms. PLoS ONE 2011; 6: e17232.
El-ShamyA , Shoji I, El-Akel W.et al. Sequence heterogeneity in NS5A of hepatitis c virus genotype 4 predicts clinical outcome of pegylated-interferon/ribavirin therapy. J Clin Microbiol, 2012; 50: 3886–92.
Papastergiou V, Dimitroulopoulos D, Skorda L, et al. Predictors of sustained virological response in Greek and Egyptian patients with hepatitis C genotype 4: does ethnicity matter? J Med Virol 2012; 84: 1217–23.
Wirth S, Ribes-Koninckx C, Calzado MA, et al. High sustained virologic response rates in children with chronic hepatitis C receiving peginterferon alfa-2b plus ribavirin. J Hepatol 2010; 52: 501–7.
Dimitroulopoulos D, Elefsiniotis I, Pavlidis C., et al. European vs. Egyptian HCV-4 patients with elevated baseline HCV RNA, treated with PEG-IFN-α2a and ribavirin: the role of rapid and early virologic response.. Hepat Mon 2010; 10: 193–8.
Roulot D, Bourcier V, Grando V, et al. Epidemiological characteristics and response to peginterferon plus ribavirin treatment of hepatitis C virus genotype 4 infection. J Viral Hepat 2007; 2007: 460–7.
Moucari R, Ripault MP, Martinot-Peignoux M, et al. Insulin resistance and geographical origin: major predictors of liver fibrosis and response to peginterferon and ribavirin in HCV-4. Gut 2009; 58: 1662–9.
Gad RR, Males S, El Makhzangy H, et al. Predictors of a sustained virological response in patients with genotype 4 chronic hepatitis C. Liver Int 2008; 28: 1112–9.
De Careaga BO. Predictive factors for response to treatment of chronic hepatitis C. Ann Hepatol 2006; 5(suppl. 1): S24–8.
Esmat G, El Akel W, Metwally M., et al. Improvement of steatosis after interferon therapy in HCV genotype 4 is related to weight loss. Indian J Gastroenterol 2009; 28: 45–8.
El-Shazly Y, Rafeek M, Al-Swaff R. Effect of well controlled diabetes mellitus on sustained virologic response in chronic HCV genotype 4 infected patients. Journal of Diabetology 2012; 2: 3.
Khattab M, Eslam M, Sharwae MA, et al. Insulin resistance predicts rapid virologic response to peginterferon/ribavirin combination therapy in hepatitis C genotype 4 patients. Am J Gastroenterol 2010; 105: 1970–7.
Khattab M, Emad M, Abdelaleem A, et al. Pioglitazone improves virological response to peginterferon alpha-2b/ribavirin combination therapy in hepatitis C genotype 4 patients with insulin resistance. Liver Int 2010; 30: 447–54.
Unicef country statistics. Available at www.unicef.org/infobycountry/egypt_statistics.
El-Zayadi A, Hepatitis B. Virus infection the Egyptian situation. Arab J Gastroenterol 2007; 8: 94–8.
Sterling RK, Sulkowski MS. Hepatitis C virus in the the setting of HIV OR Hepatitis B virus coinfection. Seminars Liver Dis 2004; 4: 1–12.
Sakuma I, Enomoto N, Kurosaki M, et al. Differntial effect of interferon on hepatitis C virus Ib quasispecies in the nonstructural protein 5A gene. J Infect Dis 1999; 180: 1001–9.
Brechot C, Thiers V, Kremsdorf D, et al. Persistent hepatitis B virus infection in subjects without hepatitis B surface antigen: clinically significant or purely “occult”? Hepatol 2001; 34: 194–203.
Elsharkawy A, Esmat G, Elraziky M, et al. HCV/Schistosomiasis coinfection: impact on fibrosis and response to pegylated interferon and Ribavirin therapy in chronic HCV patients. J Hepatol 2012; 56(Suppl): S61.
Esmat G, El-Bendary M, Zakarya S, Ela MA, Zalata K. Role of Helicobacter pylori in patients with HCV-related chronic hepatitis and cirrhosis with or without hepatocellular carcinoma: possible association with disease progression. J Viral Hepat 2012; 19: 473–9.
Asselah T, Marcellin P. Direct acting antivirals for the treatment of chronic hepatitis C: one pill a day for tomorrow. Liver Int 2012; 32(Suppl. 1): 88–102.
Manns MP, Foster GR, Rockstroh JK, et al. The way forward in HCV treatment-finding the right path. Nat Rev Drug Discov 2007; 6: 991–1000.
Benhamou Y, Moussalli J, Ratziu V, et al. Results of a proof of concept study (C210) of telaprevir monotherapy and in combination with peginterferon alfa-2a and ribavirin in treatment-naïve genotype 4 HCV patients. J Hepatol 2009; 50(Suppl): S6.
Seiwert SD, Andrews SW, Jiang Y, et al. Preclinical characteristics of the hepatitis C virus NS3/4A protease inhibitor ITMN-191 (R7227). Antimicrob Agents Chemother 2008; 52: 4432–41.
Moreno C, Berg T, Tanwandee T, et al. Antiviral activity of TMC435 monotherapy in patients infected with HCV genotypes 2–6: TMC435-C202, a phase IIa, open-label study. J Hepatol 2012; 56: 1247–53.
McHutchison JG, Manns M, Patel K, et al. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology 2002; 123: 1061–9.
Dienstag JL, McHutchison JG. American Gastroenterological Association technical review on the management of hepatitis C. Gastroenterology 2006; 130: 231–64.
McCaughan GW, Omata M, Amarapurkar D, et al. APASL Consensus statements on the diagnosis, management and treatment of hepatitis C virus infection. APASL Hepatitis C Working Party, et al.. J Gastroenterol Hepatol 2007;22 L615–33.
Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa 2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet 2001; 358: 958–65.
Khattab MA, Ferenci P, Hadziyannis SJ, et al. Management of hepatitis C virus genotype 4: recommendations of an international expert panel. J Hepatol 2011; 54: 1250–62.
Ferenci P, Fried MW, Shiffman ML, et al. Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin. J Hepatol 2005; 43: 425–33.
Kamal SM, El Kamary SS, Shardell MD, et al. Pegylated interferon alpha-2b plus ribavirin in patients with genotype 4 chronic hepatitis C: the role of rapid and early virologic response. Hepatology 2007; 46: 1732–40.
Ferenci P, Laferl H, Scherzer TM, et al. Peginterferon alfa-2a and ribavirin for 24 weeks in hepatitis C type 1and 4 patients with rapid virological response. Gastroenterology 2008; 135: 451–8.
Estrabaud E, Vidaud M, Marcellin P, Asselah T. Genomics and HCV infection: progression of fibrosis and treatment response. J Hepatol 2012; 57: 1110–25.